UMMS Taps Four-Person Board to Head Planned RNA Therapeutics Institute

In addition to assigning responsibility of the institute to the four-member group, rather than a single director, UMMS has also expanded the center's focus to include all RNA therapeutics, not just ones based on RNAi.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.